{
    "Trade/Device Name(s)": [
        "Tidepool Loop"
    ],
    "Submitter Information": "Tidepool Project",
    "510(k) Number": "K203689",
    "Predicate Device Reference 510(k) Number(s)": [
        "K200467"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QJI"
    ],
    "Summary Letter Date": "January 23, 2023",
    "Summary Letter Received Date": "May 26, 2022",
    "Submission Date": "May 26, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1356"
    ],
    "Regulation Name(s)": [
        "Interoperable Automated Glycemic Controller"
    ],
    "Analyte Class(es)": [
        "endocrine",
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose",
        "HbA1c"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid",
        "Blood (for HbA1c)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "iPhone (iOS 15+)",
        "Apple Watch (watchOS 6.1+)",
        "Compatible ACE insulin infusion pumps",
        "Dexcom G6 integrated continuous glucose monitor"
    ],
    "Method(s)/Technology(ies)": [
        "Mobile application algorithm",
        "Continuous glucose monitoring",
        "Predictive modeling"
    ],
    "Methodologies": [
        "Automated glycemic control",
        "Hybrid closed loop",
        "Bolus recommendation technology"
    ],
    "Submission Type(s)": [
        "Software",
        "System",
        "Mobile application",
        "Algorithm",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for Tidepool Loop interoperable mobile application using algorithmic technology to control insulin delivery with iCGM and ACE pumps for type 1 diabetes management",
    "Indications for Use Summary": "Intended for automatic adjustment and recommendation of insulin delivery in persons (6+ years) with type 1 diabetes mellitus using compatible iCGM and ACE pumps, for single patient, prescription use.",
    "fda_folder": "Clinical Chemistry"
}